Accolade (NASDAQ:ACCD – Get Rating) posted its quarterly earnings information on Monday. The corporate reported ($0.56) earnings per share (EPS) for the quarter, lacking the consensus estimate of ($0.43) by ($0.13), Briefing.com experiences. Accolade had a damaging return on fairness of 26.12% and a damaging web margin of 114.56%. The enterprise had income of $90.95 million for the quarter, in comparison with analysts’ expectations of $87.53 million. Throughout the identical quarter within the prior yr, the agency earned $0.31 earnings per share. Accolade’s income for the quarter was up 9.0% in comparison with the identical quarter final yr.
Accolade Inventory Efficiency
ACCD stock traded up $0.31 throughout buying and selling on Monday, reaching $7.74. 929,696 shares of the corporate’s inventory have been exchanged, in comparison with its common quantity of 674,532. The corporate has a fast ratio of three.33, a present ratio of three.33 and a debt-to-equity ratio of 0.56. Accolade has a 1-year low of $4.61 and a 1-year excessive of $24.95. The corporate’s fifty day shifting common value is $8.53 and its 200-day shifting common value is $10.01. The agency has a market cap of $556.81 million, a PE ratio of -1.34 and a beta of 1.36.
Institutional Inflows and Outflows
Numerous institutional buyers have not too long ago added to or lowered their stakes in ACCD. First Republic Funding Administration Inc. acquired a brand new place in Accolade throughout the 2nd quarter value $75,000. Prudential Monetary Inc. acquired a brand new stake in shares of Accolade within the second quarter valued at $103,000. Ensign Peak Advisors Inc lifted its holdings in shares of Accolade by 1,022.2% within the third quarter. Ensign Peak Advisors Inc now owns 13,130 shares of the corporate’s inventory valued at $150,000 after shopping for a further 11,960 shares throughout the interval. Walleye Capital LLC acquired a brand new stake in shares of Accolade within the second quarter valued at $159,000. Lastly, AQR Capital Administration LLC acquired a brand new stake in shares of Accolade within the second quarter valued at $169,000. Institutional buyers and hedge funds personal 79.01% of the corporate’s inventory.
Wall Road Analysts Forecast Development
A number of equities analysis analysts have issued experiences on the corporate. Credit score Suisse Group lifted their value goal on Accolade from $9.00 to $11.00 and gave the inventory a “impartial” ranking in a report on Friday, October seventh. SVB Leerink boosted their value goal on Accolade from $8.00 to $13.00 and gave the corporate a “market carry out” ranking in a report on Friday, October seventh. Wells Fargo & Firm boosted their value goal on Accolade from $8.00 to $10.00 and gave the corporate an “equal weight” ranking in a report on Wednesday, October twelfth. Piper Sandler boosted their value goal on Accolade from $12.00 to $13.00 and gave the corporate an “chubby” ranking in a report on Tuesday, October 4th. Lastly, The Goldman Sachs Group boosted their value goal on Accolade from $14.50 to $16.00 and gave the corporate a “purchase” ranking in a report on Friday, October seventh. Seven equities analysis analysts have rated the inventory with a maintain ranking and 7 have assigned a purchase ranking to the corporate. Primarily based on information from MarketBeat, Accolade has a median ranking of “Average Purchase” and a median value goal of $14.73.
Accolade Firm Profile
Accolade, Inc, along with its subsidiaries, develops and gives technology-enabled options that assist individuals to grasp, navigate, and make the most of the healthcare system and their office advantages in america. The corporate provides a platform with cloud-based expertise and multimodal assist from a staff of well being assistants and clinicians, together with nurses, doctor medical administrators, and behavioral well being specialists.
This prompt information alert was generated by narrative science expertise and monetary information from MarketBeat so as to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to email@example.com.
Earlier than you think about Accolade, you may need to hear this.
MarketBeat retains monitor of Wall Road’s top-rated and finest performing analysis analysts and the shares they suggest to their purchasers each day. MarketBeat has recognized the five stocks that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Accolade wasn’t on the checklist.
Whereas Accolade at present has a “Average Purchase” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.